Follow
Oncology Venture AS
Nasdaq First North Sweden (Sweden)
Oncology Venture AS, formerly Medical Prognosis Institute A/S is engaged in the development of anticancer medicines. It is developing six precision medicine projects to treat different types of cancer. The drug candidates in the pipeline have been evaluated in a broad variety of different cancer types ranging from more common cancers such as breast and prostate cancer to cancer types such as glioblastoma and multiple myeloma. Its pipeline products comprise of LiPlaCis, 2X-121, Irofulven, Dovitinib, APO010, Oncology Venture AS, formerly Medical Prognosis Institute A/S is engaged in the development of anticancer medicines. It is developing six precision medicine projects to treat different types of cancer. The drug candidates in the pipeline have been evaluated in a broad variety of different cancer types ranging from more common cancers such as breast and prostate cancer to cancer types such as glioblastoma and multiple myeloma. Its pipeline products comprise of LiPlaCis, 2X-121, Irofulven, Dovitinib, APO010, and 2X-111.

Read more

Sector:
HEALTH CARE
>
Drug Manufacturers - Specialty & Generic
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
OV
DK0060732477
Nasdaq First North Sweden
Sweden (SE)
Details of share in Oncology Venture AS with ticker OV
Status
Active
Order book id
Amount of instruments
70 707 499
Par value
0.0500
Market cap
Currency
SEK
Segment
First North
Terms
Type
Price
Pre-money valuation
Time
New issue
14.80 SEK
349.5M SEK
14 Jun - 29 Jun 2017
Share issue in Oncology Venture AS
Former company name
Medical Prognosis Institute A/S
Market
Nasdaq First North Sweden
Subscription period
14 Jun - 29 Jun 2017
Subscription price
Price per share
14.80 SEK
Target to raise
12 000 000 SEK
Types
Share issue
Pre-money valuation
349 500 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Preference right 1:29. For each existing share one (1) subscription right is received. Twenty nine (29) subscription rights entitle to subscribe for one (1) new share.
Type
Price
Pre-money valuation
Time
New issue
4.00 SEK
201.2M SEK
17 Apr - 02 May 2019
Share issue in Oncology Venture AS
Market
Nasdaq First North Sweden
Subscription period
17 Apr - 02 May 2019
Subscription price
4.00 SEK
Price per share
4.00 SEK
Target to raise
100 600 000 SEK
Types
Share issue
Pre-money valuation
201 200 000 SEK
Subscription block size
Minimum subscription
Record date
12 Apr 2019
Offer status
Closed
Listing status
Listed
Issue terms
Pre-emption 1:2. For each one (1) share one (1) subscription right is received. Two (2) subscription rights entitle the holder to subscribe for one (1) new unit consisting of one (1) share and one (1) warrant.
Type
Price
Pre-money valuation
Time
New issue
2.00 SEK
140M SEK
2019
Share issue in Oncology Venture AS
Market
Nasdaq First North Sweden
Subscription year
2019
Subscription price
10.00 SEK
Price per share
2.00 SEK
Target to raise
100 000 000 SEK
Types
Share issue
Pre-money valuation
140 000 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Active
Listing status
Listed
Issue terms
Rights issue. Preference right 5:7. For every one (1) subscribed and paid share, one (1) subscription option is also obtained.
Comments for offer & related information
Guarantees and subscription commitments in excess of SEK 100 million have already been received from guarantors and shareholders. The warrants will have a strike price of SEK 6.00 and a maturity of twenty-four (24) months.
Type
Ticker
ISIN
Market
OPTION
OV TO 1
DK0061139581
Nasdaq First North Sweden
Sweden (SE)
Details of option in Oncology Venture AS with ticker OV TO 1
Status
Active
Order book id
176918
Amount of instruments
20 166 221
Market cap
Currency
SEK
Trading period
24 Jul 2019 - 22 May 2020
Terms
One (1) Investor Warrant confers the right to subscribe one (1) Additional Share of nominal DKK 0.05 in the Company.
Type
Price
Pre-money valuation
Time
Exercise
7.50 SEK
-
01 Jun - 07 Jun 2019
01 Sep - 06 Sep 2019
01 Dec - 06 Dec 2019
Option exercise terms for OV TO 1
Market
Nasdaq First North Sweden
Exercise period(s)
01 Jun - 07 Jun 2019
01 Sep - 06 Sep 2019
01 Dec - 06 Dec 2019
Exercise price
7.50 SEK
Status
Upcoming
Issue terms
One (1) Investor Warrant confers the right to subscribe one (1) Additional Share of nominal DKK 0.05 in the Company.
People
Number of Employees
12 people
Peter Buhl Jensen
CEO
Frank Knudsen
Chairman of the board
Peter Buhl Jensen
Board member
Frank Knudsen
Board member
Gunnar Magnus Severus Modée Persson
Board member
Steen Meier Knudsen
Board member
Niels Johansen
Board member
Company Details
Sector
HEALTH CARE

Address
VENLIGHEDSVEJ 1
Zip code
2970
City/district
HØRSHOLM
Country
Denmark (DK)
Registration number
28106351
LEI code
213800FKAPK1MPJ18Q79
First trade date
27 Jun 2016
Company former names
Medical Prognosis Institute A/S
03 Sep 2018
Registration date
09 Sep 2004
Short name
Oncology Venture

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More